TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03004989

Intervention type: BEHAVIORAL
Intervention: Programme
Description: The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
Study: NCT03340961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29 Extended Release Capsules (40 mg)
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29 Extended Release Capsules (20 mg)
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraycea® (doxycycline) Capsules
Description: Oral Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Oral Treatment
Study: NCT04283565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of CVRF by a motivationnal interviewing.
Description: The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of CVRF by a motivationnal interviewing.
Description: The strategies will be associated according to a 2\*2 factorial design in order to obtain 4 arms
Study: NCT00763906

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: norepinephrine infused at the clinician's discretion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infused under computerized fuzzy logic control
Study: NCT00983736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks.
Study: NCT00914563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIDCO Lithium Dilution Cardiac Output
Description: Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
Study: NCT00579566

Intervention type: OTHER
Intervention: Specimen protocol
Description: The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
Study: NCT03583086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Given by mouth
Study: NCT00914563

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard Care
Description: We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
Study: NCT02741570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab/Erbitux
Study: NCT03583086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study: NCT02741570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Platinol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/Paraplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil/Adrucil
Study: NCT02445937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER II
Description: The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists.
Study: NCT04267731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VMK223
Description: Heat killed and purified Bifidobacterium breve polysaccharide-based extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VMK223
Description: Heat killed and purified Bifidobacterium breve polysaccharide-based extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VMK223
Description: Heat killed and purified Bifidobacterium breve polysaccharide-based extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Bulking agent in food production without probiotic properties
Study: NCT01058512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV-205
Description: There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days
Study: NCT01482897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: comparator : physiological solution
Description: anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
Study: NCT02004145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology
Description: The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Condition
Description: The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
Study: NCT01813838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACADESINE 140mg/kg/d
Description: 3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACADESINE 210mg/kg/d
Description: 3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACADESINE 315mg/kg/d
Description: 3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d
Study: NCT01895933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5ml surgishield
Description: in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36\~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site
Study: NCT04161378

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging
Description: * Transthoracic echocardiography~* Late gadolinium enhancement CMR

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging
Description: * Transthoracic echocardiography~* Late gadolinium enhancement CMR

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis
Description: * complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis
Description: * complete blood count~* biochemistry~* hs-CRP, MMPs, IL6, NT-pro-BNP
Study: NCT01707589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The new sensor is not on the market. We have named it Elfi-sensor.
Description: Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
Study: NCT04533399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Description: Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
Study: NCT02608450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 cream, 1%
Description: CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Study: NCT03700450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
Study: NCT04306289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, neuropathic pain.
Study: NCT02581930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00000262

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4% Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% sevoflurane

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02517385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine
Description: Pharmaceutical form:Paste Route of administration: Oral
Study: NCT03042247

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET/TC and FDG PET/MRI
Description: Combined assessment with FDG PET/TC and PET/MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG PET/TC and FDG PET/MRI
Description: Combined assessment with FDG PET/TC and PET/MRI
Study: NCT00717340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib (AV-951) + paclitaxel
Description: Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks).
Study: NCT01525043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg BID for the first 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera patch twice daily
Description: 1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera patch for 12hrs/day
Description: 1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 500mg bid
Study: NCT03343080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8% lidocaine plus 0.76% sodium bicarbonate
Description: At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Air
Description: At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
Study: NCT02893826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-1962 (nimodipine microparticles)
Study: NCT01525043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera
Description: Topical appication of single patch to elbow for 12hrs/day
Study: NCT03709797

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling in infraspinatus muscle
Description: Dry needling technique with multiple rapid needle insertion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling in infraspinatus muscle
Description: Dry needling technique with multiple rapid needle insertion.
Study: NCT03160976

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryolipolysis
Description: First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
Study: NCT02522104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siklos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siklos
Study: NCT01525043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera
Description: Single patch applied to elbow for 4hrs/twice daily
Study: NCT02522104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siklos
Study: NCT02893826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nimodipine
Study: NCT02067663

Intervention type: DEVICE
Intervention: Paragard
Description: The IUD will be placed as part of standard clinical care.

Intervention type: DRUG
Intervention: Mirena
Description: The IUD will be placed as part of standard clinical care.
Study: NCT04488744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s
Description: Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s
Description: Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s
Description: Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s
Description: Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
Study: NCT03201133

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular evaluation
Description: (1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular evaluation
Description: (1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
Study: NCT04488744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s
Description: Nicotine infusion 0.2 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries), 0.2mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries), 1.0 mg nicotine delivered over 2.5 minutes (5 pulsed-nicotine deliveries) and 1.0 mg nicotine delivered over 10 min (20 pulsed-nicotine deliveries).
Study: NCT06119438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: Aromatherapy is a TAT (Tapas Acupressure technique) method in which essential oils created from fragrant parts of plants are absorbed from the body and show their effects. The therapeutic, disease-relieving or preventive properties of essential oils are utilized
Study: NCT04384107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in PCV13 plus 2 additional serotypes (22F, 33F) in each subcutaneous 0.5 mL single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each subcutaneous 0.5 mL single dose.
Study: NCT01444586

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.